The shelf filing alongside a 98.8% revenue decline and ongoing cash burn signals that Arvinas will likely tap the ATM facility to extend its runway. Monitor the pace of ATM sales in upcoming filings and the Q4 2026 cash position for signs of accelerated dilution.
Drugs in focus
ARVN drug pipeline →ARV-393
● Neutral Named in this S-3- Impact
- Phase
- Phase 1
- Time to market
- At least several years away. The drug is in Phase 1 dose escalation (estimated primary completion March 2028), requiring Phase 2/3 trials and regulatory review before any potential approval.
- Next catalyst
- None dated
What to watchThe next hard catalyst is the initial Phase 1 monotherapy dose escalation data for ARV-393, submitted for presentation at the ASH Annual Meeting (Dec 12-15, 2026). Positive safety and early efficacy signals could re-rate the stock from near its 52-week low; any safety or tolerability concerns would be a setback for the BCL6 degrader program. A second data readout is expected in mid-2027.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 4 $7.42entry
- T+1 · 12d ago −11.73%α −7.32% · $6.55
- T+5 · 6d ago −6.87%α −5.96% · $6.91
- T+8 · todayOpen
- T+20 · in 16d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Arvinas filed a universal shelf registration statement to offer up to $400M in securities, including a $200M ATM equity facility with Piper Sandler and Cantor Fitzgerald. The filing comes on the same day as a Q3 2026 earnings release showing a 98.8% revenue decline to $0.5M and a cash burn of $123M in the first nine months, with cash reserves of $558.9M. The shelf provides financial flexibility but signals potential dilution as the company funds operations through its clinical pipeline without near-term product revenue.
Key Financial Metrics
Key Facts
- S-3 registration for up to $400M in securities, including a $200M ATM equity offering
- ATM facility with Piper Sandler and Cantor Fitzgerald, up to 3.0% agent commissions
- Filed same day as Q3 2026 earnings: revenue of $0.5M, down 98.8% from $41.9M a year ago
- Cash and marketable securities of $558.9M as of September 30, 2026, down from $685.4M at year-end 2025
- Cash used in operations of $123.0M in the first nine months of 2026
- Market cap of $517M; ATM size of $200M represents ~39% of market cap
- 65.5M shares outstanding as of September 30, 2026; up to 26.6M additional shares at $7.52 per share
Financial Impact
Up to $200M in potential ATM proceeds, representing ~39% of current market cap of $517M. Cash burn of $123M in 9 months implies ~$164M annualized, providing roughly 3.4 years of runway at current cash levels.
Risk Factors
- Potential dilution of up to 41% from full ATM utilization at current prices
- Revenue collapse from Pfizer collaboration transition leaves no near-term product revenue
- Cash burn of $123M in 9 months may accelerate if clinical trial costs increase
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001628280-26-069595 |
| Exhibit: exhibit46-sx3.htm | 0001628280-26-069595 |
Track record
21 reports on ARVN
5 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +28.62% at T+60 after the Feb 23, 2026 report. 8 of 8 went positive at some point.
Filters
- Nov 3, 202613d ago S-3 Bearish 5/10 Viewing Entry $7.42 to $6.55 Now $6.77 +8.76% ▲ +11.73% +7.32% vs SPY
- Nov 3, 202613d ago 8-K Bearish 5/10 No price data
- Nov 3, 202613d ago Press Release Neutral 4/10 Entry $7.09 to $7.42 Now $6.77 −4.51% ▲ +4.65% +3.00% vs SPY
- Sep 4, 202610w ago 144 Neutral 3/10 Entry $9.08 to $8.76 Now $6.77 −25.44% ▼ −3.52% −3.06% vs SPY
- Jun 22, 202621w ago 8-K Neutral 3/10 Entry $8.14 to $8.05 Now $6.77 −16.83% ▼ −1.11% −1.06% vs SPY
- Jun 2, 202623w ago 8-K Bearish 6/10 Entry $7.70 to $7.74 Now $6.77 +12.08% ▼ −0.52% −0.12% vs SPY
- May 12, 202626w ago 8-K Mixed 6/10 No price data
- May 12, 202626w ago 8-K Bullish 7/10 Entry $9.57 to $9.87 Now $6.77 −29.26% ▲ +3.13% +2.56% vs SPY
- May 12, 202626w ago Press Release Bearish 8/10 Entry $9.57 to $9.87 Now $6.77 +29.26% ▼ −3.13% −2.56% vs SPY
- May 8, 202627w ago 144 Neutral 2/10 Entry $9.66 to $9.57 Now $6.77 −29.92% ▼ −0.93% −0.80% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers